EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France

Loïg Gaugain, Hélène Cawston iD, Coline Dubois de Gennes, Javier Sanchez Alvares, Pierre Nahon, Benjamin Mazaleyrat, Clément Le Dissez

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0280442 ↗

Kurz gefasst

Leitlinie in der Zeitschrift PLOS ONE, 2023. Verfasst von Loïg Gaugain und 6 weiteren Autor:innen. Beteiligte Einrichtung: Amaris Consulting, Montréal, Canada. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims The IMbrave150 clinical trial assessed the efficacy and safety of atezolizumab in combination with bevacizumab (ATZ+BVA) versus sorafenib in adults with advanced/unresectable hepatocellular carcinoma, who have not received prior systemic treatment. Our aim was to assess the cost-effectiveness of ATZ+BVA versus sorafenib in France based on an updated prices and considering French National real-world data, to confirm the initial recommendations from the Heath Technology Assessment submission published in 2021, and provide additional visibility to decision-makers reflecting current clinical practice.

Methods

A partition survival model was developed to project clinical outcomes, quality of life, and costs of patients with HCC treated with ATZ+BVA versus sorafenib over a lifetime horizon. Survival outcomes were extrapolated via parametric functions for both treatment strategies. Quality of life (EQ-5D-5L, French tariffs) were sourced from IMbrave150. The Guyot method was considered as a scenario analysis by integrating retrospective real-world data extracted from the French Health Insurance Database to refine long term survival extrapolations.

Results

In the reference case, ATZ+BVA was associated with 0.61 additional Quality Adjusted Life Years (QALYs) compared to sorafenib (1.95 vs 1.35), and an incremental cost of €92,704. The incremental cost-utility ratio (ICUR) was 152,974 €/QALY gained. Adjusting the survival curves with French external evidence led to a 14% ICUR reduction (131,163 €/QALY).

Conclusions

ATZ+BVA is a cost-effective strategy based on the range recently published for the value of a QALY in France and offers better chances of survival to patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsAdultHumansBevacizumabCost-Benefit AnalysisSorafenibRetrospective StudiesQuality of LifeQuality-Adjusted Life YearsAntibodies, Monoclonal, Humanized

Substanzen

BevacizumabSorafenibatezolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Amaris Consulting, Montréal, Canada.
  • Amaris Consulting, Paris, France.
  • Amaris Consulting, London, United-Kingdom.
  • Roche SAS, Boulogne-Billancourt, France.
  • AP-HP, Liver Unit, Bobigny, France.
  • Université Sorbonne Paris Nord, Bobigny, France.

ORCID-Profile: Hélène Cawston

Förderung

  • Roche

Zitieren

APA

Gaugain, L., Cawston, H., Dubois de Gennes, C., Sanchez Alvares, J., Nahon, P., Mazaleyrat, B., & Le Dissez, C. (2023). Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France. PLOS ONE. https://doi.org/10.1371/journal.pone.0280442

Vancouver

Gaugain L, Cawston H, Dubois de Gennes C, Sanchez Alvares J, Nahon P, Mazaleyrat B, et al. Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France. PLOS ONE. 2023. doi:10.1371/journal.pone.0280442

BibTeX
@article{Gaugain2023,
  author = {Gaugain, Loïg and Cawston, Hélène and Dubois de Gennes, Coline and Sanchez Alvares, Javier and Nahon, Pierre and Mazaleyrat, Benjamin and Le Dissez, Clément},
  title = {Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0280442}
}
Kostenlos starten →